Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | PER2 | O15055 | 1/20 | 0.30 |
| ▸ | CRY2 | Q49AN0 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10245854 | 0.94 | PIK3CD (0.47) | PIK3CDKDM4EGRM2ALDH1A1CA1 | |
| SCHEMBL1106523 | 0.86 | — | — | |
| SCHEMBL908022 | 0.79 | PIK3CD (0.46) | PIK3CDKDM4EGRM2ALDH1A1CA1 | |
| SCHEMBL22067189 | 0.77 | PIK3CD (0.49) | PIK3CDKDM4EGRM2 | |
| SCHEMBL19091731 | 0.75 | PIK3CD (0.46) | PIK3CDKDM4EGRM2 | |
| SCHEMBL22596111 | 0.75 | PIK3CD (0.46) | PIK3CDKDM4EGRM2CA1CA9 | |
| SCHEMBL14607449 | 0.75 | PIK3CD (0.46) | PIK3CDKDM4EGRM2CA1CA9 | |
| SCHEMBL19766973 | 0.74 | PIK3CD (0.36) | PIK3CD | |
| SCHEMBL22065917 | 0.74 | PIK3CD (0.45) | PIK3CDKDM4EGRM2ALDH1A1 | |
| SCHEMBL12129117 | 0.74 | PIK3CD (0.38) | PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151547-A1 | TARGETED DEGRADATION OF VAV1 | MONTE ROSA THERAPEUTICS, INC. (US) | 2024-07-18 | — | — | WO | disclosed |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | DECIPHERA PHARMACEUTICALS, LLC | 2023-02-09 | — | — | US | disclosed |
| US-20220411429-A1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BIOGEN MA INC. | 2022-12-29 | — | — | US | disclosed |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | MERCK PATENT GMBH (DE) | 2019-08-27 | — | — | US | disclosed |
| US-10233152-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2019-03-19 | — | — | US | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-20180127369-A1 | LSD1 Inhibitors | Mirati Therapeutics, Inc. | 2018-05-10 | — | — | US | disclosed |
| US-20180009798-A1 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer | MIDWESTERN UNIVERSITY | 2018-01-11 | — | — | US | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809541-B2 | LSD1 inhibitors | Mirati Therapeutics, Inc. (US) | 2017-11-07 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
| US-7521470-B2 | Factor Xa inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20090054408-A1 | Monocyclic anilide spirolactam cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090054408-A1 | Monocyclic anilide spirolactam cgrp receptor antagonists | MERCK SHARP & DOHME LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090030045-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-20070259924-A1 | FACTOR XA INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2007-11-08 | — | — | US | disclosed |
| US-7192954-B2 | Monocyclic anilide spirohydantoin CGRP receptor antagonists | MERCK & CO., INC. (US) | 2007-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10233152-B2 | LSD1 inhibitors | KDM1B, KDM1A, KDM3A | PIK3CD 3138/4885KDM4E 14/4885GRM2 760/4885 |
| US-20090030045-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PIK3CD 1521/4885KDM4E 2361/4885GRM2 4801/4885 |
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | PIK3CD 1372/4885KDM4E 364/4885GRM2 2893/4885 |
| US-10392375-B2 | Heteroaryl compounds as IRAK inhibitors and uses thereof | IRAK2, IRAK3, IRAK1 | PIK3CD 137/4885KDM4E 729/4885GRM2 1427/4885 |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | PIK3CD 2030/4885KDM4E 2542/4885GRM2 1562/4885 |
| US-20230039712-A1 | PHENYLAMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF | BECN1, SQSTM1, ATG7 | PIK3CD 345/4885KDM4E 1256/4885GRM2 3321/4885 |
| US-20220411429-A1 | CONDENSED PYRIDAZINE OR PYRIMIDINE AS BTK INHIBITORS | BTK, CDK2, SYK | PIK3CD 72/4885KDM4E 1694/4885GRM2 3045/4885 |
| US-20090054408-A1 | Monocyclic anilide spirolactam cgrp receptor antagonists | BDKRB1, BDKRB2, CALCRL | PIK3CD 3568/4885KDM4E 3491/4885GRM2 703/4885 |
| US-20070259924-A1 | FACTOR XA INHIBITORS | TFPI, F12, F11 | PIK3CD 1521/4885KDM4E 2361/4885GRM2 4801/4885 |
| US-20180009798-A1 | Inhibitors of Beta-Hydroxylase for Treatment of Cancer | ASPH, CYP46A1, ALDH7A1 | PIK3CD 1609/4885KDM4E 465/4885GRM2 2930/4885 |
| US-20180127369-A1 | LSD1 Inhibitors | KDM1B, KDM1A, KDM3A | PIK3CD 3138/4885KDM4E 14/4885GRM2 760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.